| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Lodoxamide Tromethamide (U-42585E), the Tromethamide salt of Lodoxamide, is an antiallergic drug acting as a potent GPR35 agonist with an EC50 of 1.61 nM in a β-arrestin-2 interaction assay using CHO-K1 cells expressing the human receptor. It blocks the release of histamine in isolated rat peritoneal mast cells (IC50s = 0.1-50 µM) when compound 48/80, anti-IgE, or A23187 is applied.It also prevents mast cells from receiving calcium influx when A23187 is applied. At a concentration of 10 µg/ml, it decreases antigen-induced histamine release from rat conjunctival tissue by 46% in vitro. Lodoxamine (0.1 and 10%, w/v) decreases mast cell degranulation in a topical ovalbumin challenge and dose-dependently lowers the acute hypersensitivity response in rat conjunctiva in vivo. Lodoxamide-containing formulations have been utilized to treat keratitis and vernal conjunctivitis.
| ln Vitro |
|
|
|---|---|---|
| ln Vivo |
|
|
| References |
|
|
| Additional Infomation |
Lodoxamide Tromethamine is the tromethamide salt form of lodoxamide, a synthetic mast cell stabilizing compound with anti-inflammatory activity. Upon administration to the eye, lodoxamide tromethamide inhibits type I immediate hypersensitivity reaction by preventing the antigen-stimulated calcium influx into mast cells, thereby inhibiting release of histamine. Lodoxamide tromethamide also prevents the release of slow-reacting substances of anaphylaxis (SRS-A) and inhibits eosinophil chemotaxis.
See also: Lodoxamide (has active moiety). |
| Molecular Formula |
C15H17CLN4O9
|
|---|---|
| Molecular Weight |
553.90
|
| Exact Mass |
553.142
|
| Elemental Analysis |
C, 41.20; H, 5.10; Cl, 6.40; N, 12.64; O, 34.66
|
| CAS # |
63610-09-3
|
| Related CAS # |
Lodoxamide; 53882-12-5
|
| PubChem CID |
11192129
|
| Appearance |
White to light yellow solid powder
|
| Boiling Point |
827.5ºC at 760 mmHg
|
| Flash Point |
454.3ºC
|
| Hydrogen Bond Donor Count |
12
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
37
|
| Complexity |
543
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC1C(=C([H])C(C#N)=C([H])C=1N([H])C(C(=O)O[H])=O)N([H])C(C(=O)O[H])=O.O([H])C([H])([H])C(C([H])([H])O[H])(C([H])([H])O[H])N([H])[H].O([H])C([H])([H])C(C([H])([H])O[H])(C([H])([H])O[H])N([H])[H]
|
| InChi Key |
JJOFNSLZHKIJEV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H6ClN3O6.2C4H11NO3/c12-7-5(14-8(16)10(18)19)1-4(3-13)2-6(7)15-9(17)11(20)21;2*5-4(1-6,2-7)3-8/h1-2H,(H,14,16)(H,15,17)(H,18,19)(H,20,21);2*6-8H,1-3,5H2
|
| Chemical Name |
2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-chloro-5-cyano-3-(oxaloamino)anilino]-2-oxoacetic acid
|
| Synonyms |
Lodoxamide Tromethamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~20 mg/mL (~36.1 mM)
Water: ~19 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.76 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.76 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (3.76 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8054 mL | 9.0269 mL | 18.0538 mL | |
| 5 mM | 0.3611 mL | 1.8054 mL | 3.6108 mL | |
| 10 mM | 0.1805 mL | 0.9027 mL | 1.8054 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
